P-gp inhibitor 3 

P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel^[1].

P-glycoprotein

P-gp inhibitor 3 (compound 16) (10 μM; 72 hours) has appreciable cytotoxicity in KBV cancer cells, with relatively stronger MDR reversal ability^[1].
P-gp inhibitor 3 (2.5, 5, 10 μM ; 3 hours) reverses tumor MDR by inhibiting the efflux function of P-gp^[1].
P-gp inhibitor 3 (0.25, 0.5, 1 mM; 5 minutes) can significantly increase ATP consumption in a concentration-dependent manner (p<0.01)^[1].
P-gp inhibitor 3 (10 μM; 24 hours) induces apoptosis in KBV cells in the G₂/M phase^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

P-gp inhibitor 3 (10 mg/kg; i.p., once a day, for 1 to 18 days) significantly enhances the anti-tumor activity of paclitaxel and the tumor suppression rate is 56.24%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

782.06

C₄₈H₆₇N₃O₆

2766451-11-8

O=C([C@]12[C@](CC(C)(CC2)C)([H])C3=CC[C@@]([C@@]4([C@@]([C@@](C)(C5=C(C=NO5)C4)COC(CCC(N6CCN(CC6)CC)=O)=O)([H])CC7)C)([H])[C@]7(C)[C@@]3(CC1)C)OCC8=CC=CC=C8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Huang W, et al. Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles. Eur J Med Chem. 2022;232:114207.  [Content Brief]